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MaBACKGROUND There are scarce data available on transcatheter mitral valve replacement (TMVR), and these have
been limited to procedural results, with no follow-up status reported.
OBJECTIVES The goal of this study was to evaluate the feasibility, procedural results, and 6-month follow-up
outcomes after TMVR with a mitral transcatheter heart valve (Fortis, Edwards Lifesciences, Irvine, California).
METHODS We report a series of 3 patients (mean age 71  9 years, 2 men) who had TMVR under a compassionate
clinical use program. All patients treated had functional mitral regurgitation (MR) secondary to ischemic cardiomyopathy
(prior bypass surgery in all cases; left ventricular ejection fraction between 25% and 30%) and were considered to be at
very high surgical risk (mean Society of Thoracic Surgeons score: 9.3).
RESULTS The procedure was performed through the transapical approach, and the valve was successfully implanted in
all cases, with no major complications. At hospital discharge, echocardiographic evaluation revealed trace residual MR in
2 patients and no MR in 1 patient. The mean transvalvular mitral gradient was #4 mm Hg in all patients. At the 3-month
follow-up, the valve function remained unchanged, and transesophageal echocardiography and computed tomography
showed no structural failures. All patients had improvements in functional status, in exercise capacity as evaluated by 6-
min walk test, and in quality of life. At 6-month follow-up, all patients remain alive, without hospital readmission for
heart failure and with New York Heart Association functional class #II.
CONCLUSIONS TMVR with this valve is feasible and is associated with good outcomes. Optimal valve functional results
were obtained acutely and were sustained at 6-month follow-up in all patients. Further studies with a larger number of
patients and longer follow-up are warranted. (J Am Coll Cardiol 2015;66:1011–9) © 2015 by the American College of
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6MWT = 6-min walk test
CT = computed tomography
DASI = Duke Activity Status
Index
LVEF = left ventricular ejection
fraction
LVOT = left ventricular outﬂow
tract
MR = mitral regurgitation
NYHA = New York Heart
Association
TEE = transesophageal
echocardiography
TMVR = transcatheter mitral
valve replacement
TTE = transthoracic
echocardiography
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1012conditions are required to obtain satisfactory
results, with increasing rates of procedural
failure and poorer clinical outcomes when
these criteria are not taken into account
(6–8). Therefore, a signiﬁcant proportion of
noncandidates for surgery for whom percu-
taneous mitral repair is not an appropriate
option remain.
Transcatheter mitral valve replacement
(TMVR) has recently emerged as a new ther-
apeutic option for the treatment of mitral
valve disease. However, current experience
is limited to procedural results in very few
cases worldwide (9–12), and follow-up status
has not been reported. The objective of
this study was to evaluate the feasibility,
procedural results, and 6-month follow-up
outcomes after TMVR with the mitral trans-
catheter heart valve (Fortis, Edwards Life-sciences, Irvine, California).SEE PAGE 1020METHODS
A multidisciplinary team composed of cardiac sur-
geons, interventional cardiologists, echocardiog-
raphers, and radiologists evaluated all cases. Clinical
inclusion criteria included the presence of isolated
severe mitral regurgitation (3þ or 4) and New York
Heart Association (NYHA) functional class III or IV,
despite optimal medical treatment including cardiac
resynchronization therapy, if indicated. Clinical
exclusion criteria were moderate or greater mitralE 1 The Fortis Transcatheter Heart Valve
e Fortis mitral transcatheter heart valve has 3 different parts: the a
). The paddles are opened once the prosthesis enters into the left v
e the native mitral leaﬂets. (B) Fluoroscopic images of the Fortisvalve stenosis, untreated coronary artery disease
requiring revascularization, chronic renal failure
stage >III not receiving dialysis, other concomitant
signiﬁcant valve disease, and known hypersensitivity
to nitinol. Anatomic suitably was evaluated using
echocardiography and computed tomography (CT)
scan criteria, as previously described (10).
After multidisciplinary team evaluation, all pa-
tients were considered to be at prohibitive risk for
standard surgical valve repair/replacement. All pa-
tients were evaluated and treated under a Special
Access Program approved by Health Canada. This is a
clinically oriented program that evaluates, on a case-
by-case basis, requests for access to nonmarketed
drugs or devices for treatment, diagnosis, or pre-
vention of serious or life-threatening conditions
when conventional therapies have been considered
and ruled out, have failed, are unsuitable, and/or
unavailable. After Health Canada approval, all pa-
tients provided signed informed consent for the
procedures and for retrospective data collection and
reporting.
FORTIS MITRAL TRANSCATHETER HEART VALVE. The
valve (Figure 1) comprises a self-expanding, nitinol
frame, trileaﬂet Resilia bovine pericardial tissue, an
atrial ﬂange, and 2 opposing paddles that capture the
native mitral leaﬂets and secure them to the frame,
forming the primary attachment mechanism. The
29-mm prosthesis (the only available size to date) is
crimped and loaded into a 42-F transapical delivery
system. The 29-mm valve is suitable in patients with
native annular diameter distance at the A2-P2 level
between 30 and 44 mm.trial ﬂange, the ventricular side (or valve body), and 2 paddles (black
entricular cavity and are oriented using echocardiography guidance to
valve after full deployment. AS ¼ atrial side; VS ¼ ventricular side.
FIGURE 2 Procedural Transesophageal Echocardiography Images
Transesophageal echocardiogram images obtained during transcatheter mitral valve replacement with the valve. (A) Midesophageal
intercommissural view. Finger exploration of the ventricular apex is used to locate the appropriate access point (red arrow), which allows
for appropriate coaxiality of the system with the mitral annulus while avoiding the subvalvular apparatus (red dotted line). (B) Mid-
esophageal intercommissural view. Maneuver with the Fogarty catheter to ensure that the catheter is not tangled within the mitral
chordae. (C) Transgastric short-axis view at the mitral leaﬂet and subvalvular level. The system is located at the midventricular cavity.
Paddles are opened (blue and red asterisks). This view is used to verify the perpendicularity of the paddles with respect to the mitral
annulus at the A2-P2 level. (D) Midesophageal long-axis LVOT view. Once the position of the paddles is veriﬁed, the system is advanced
to capture the mitral leaﬂets. (E) Midesophageal long-axis LVOT view showing the atrial frame released. The ventricular frame is still
unreleased. (F) Midesophageal long-axis LVOT view. The ventricular frame of the valve has been released. The nose cone is still in the LV
cavity. AL ¼ mitral anterior leaﬂet; Ao ¼ aorta; LA ¼ left atrium; LV ¼ left ventricle; LVOT ¼ left ventricular outﬂow tract; PL ¼ mitral
posterior leaﬂet; RV ¼ right ventricle.
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1013PROCEDURAL STEPS. The procedures were performed
under general anesthesia with hemodynamic moni-
toring in an operating room with ﬂuoroscopic and
echocardiographic imaging capabilities. Epidural
anesthesia was used in all patients to improve control
of post-procedural chest pain and to facilitate post-
intervention recovery. The approach consisted of
direct puncture close to the ventricular apex through
a small left lateral thoracotomy, and then the delivery
system was advanced directly through the ventricular
incision. Transesophageal echocardiography (TEE)
guided the ventricular puncture point to obtain
delivery system coaxiality with the mitral annulus
(Figure 2A). The mitral valve was crossed with aFogarty catheter (Edwards Lifesciences) to ensure
that the guide wire was free from chordal entangle-
ment (Figure 2B). To decrease the risk of wire-induced
perforation, a soft J-tip guide wire was positioned
into the right superior pulmonary vein and was sub-
sequently exchanged for a stiff J-tip guide wire with a
soft tip using a multipurpose catheter. The delivery
system with the crimped valve was advanced ante-
gradely over the stiff wire up to the midventricular
cavity. At this point, the paddles were partially
exposed, and TEE guidance was used to evaluate
their orientation (Figure 2C). After conﬁrming that the
paddles were oriented between the papillary muscles,
the paddles were fully exposed and opened in
TABLE 1 Baseline Clinical, Echocardiographic, and Computed Tomography
Characteristics
Patient 1 Patient 2 Patient 3
Baseline clinical characteristics
Age, yrs 67 65 81
Sex Male Female Male
Coronary artery disease Yes Yes Yes
Previous CABG Yes Yes Yes
Atrial ﬁbrillation/ﬂutter Yes No Yes
Peripheral vascular disease No No Yes
Previous stroke/TIA Yes No No
COPD No No No
Clearance of creatinine, ml/min 32 31 49
Heart failure hospitalizations
(past year)
2 1 1
Frailty No No No
QRS wide, ms 116 116 156
QRS morphology ILBB ILBB Paced
CRT No No Yes
STS score 7.2 8.7 12.0
Log EuroSCORE 29.9 19.5 33.1
Baseline echocardiogram
LVEF, % 25 30 30
MR mechanism Functional Functional Functional
MR grade, 1 to 4 3þ 4 3þ
PAPs, mm Hg 45 45 46
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; CRT ¼
cardiac resynchronization therapy; EuroSCORE ¼ European System for Cardiac Operative Risk
Evaluation; ILBB ¼ incomplete left branch block; LVEF ¼ left ventricular ejection fraction; MR ¼
mitral regurgitation; PAPs ¼ systolic pulmonary artery pressure; STS ¼ Society of Thoracic Sur-
geons; TIA ¼ transient ischemic attack.
TABLE 2 Procedural
Procedure time, min
Procedural success
In-hospital complicatio
Hospital stay, days
Post-MR grade, 1 to 4
Mean TM gradient, mm
Mean aortic O-G, mm H
30-day results
MR ¼ mitral regurgitation;
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1014preparation for leaﬂet capture. The delivery system
was advanced to capture the mitral leaﬂets at the A2-
P2 level (Figure 2D). After leaﬂet capture was
conﬁrmed, the atrial ﬂange was released (Figure 2E).
The valve was then released by unsheathing the
ventricular portion (Figure 2F). Rapid pacing is not
required for the delivery of the valve. We elected to
use brief, rapid pacing for catheter retrieval and
apical repair to prevent potential myocardial tears.Data and 30-Day Results
Patient 1 Patient 2 Patient 3
25 43 44
Yes Yes Yes
ns No Acute renal
failure stage 1
Minor bleeding
7 13 8
1 1 0
Hg 4 3 4
g 4.2 2.9 5
Alive/without
complications
Alive/gastrointestinal
bleeding
Alive/without
complications
O-G ¼ outﬂow gradient; TM ¼ transmitral.Anticoagulation during the procedure was obtained
with intravenous heparin, and the dose was adjusted
to obtain an activated clotting time >250 s. Aspirin
(80 mg) was administered before and after the
implant procedure, and warfarin was started after
the procedure and continued for at least 3 months.
In patients with baseline atrial ﬁbrillation, warfarin
was to be continued indeﬁnitely and aspirin was
continued for at least 3 months.
Procedural success was deﬁned as the implantation
of a functioning valve within the mitral annulus,
without intraprocedural mortality or signiﬁcant
(moderate or severe) residual MR and/or mitral
stenosis.
All in-hospital, 30-day, and follow-up events were
recorded and collected in a dedicated database.
Adverse events were deﬁned according to the Valve
Academic Research Consortium-2 criteria (13). There
was no systematic evaluation of the patients by a
neurologist. Before hospital discharge, an echocar-
diographic (transthoracic and transesophageal) eval-
uation of the valve prosthesis was performed.
FOLLOW-UP: FUNCTIONAL STATUS, EXERCISE CAPACITY,
AND QUALITY-OF-LIFE ASSESSMENT. All patients had
a clinical visit and transthoracic echocardiography
(TTE) examination at the 1- to 3-month and 6-month
follow-ups. A TEE and 3-dimensional (3D)–CT exam-
inations were also performed at the 3-month follow-
up. The presence and severity of MR were evaluated
according to guidelines (14). The 3D-CT was per-
formed to determine the integrity of the valve pros-
thesis (i.e., inspect for frame fractures) and the
anatomic relation of the valve to the left ventricle and
the left atrium.
The functional status, exercise capacity, and
quality of life of the patients were evaluated at
baseline (during the week before the procedure) and
at the 3- and 6-month follow-ups. Functional status
was evaluated using the NYHA functional class and
the Duke Activity Status Index (DASI) questionnaire.
The DASI questionnaire consists of a 12-item scale
ranging from 0 (worst) to 58.2 (best) that evaluates
the ability to perform common activities of daily
living. Exercise capacity was evaluated with the
6-min walk test (6MWT), which was conducted
according to a standardized protocol, using a 30-m
internal ﬂat corridor with 2 orange trafﬁc cones (15).
Patient quality of life was evaluated with the Kansas
Cardiomyopathy Questionnaire (16).
RESULTS
A series of 3 patients were successfully treated with
the mitral transcatheter heart valve.
FIGURE 3 Baseline and Immediate Post-Implantation Echocardiographic Images
Echocardiograms of the 3 patients following transcatheter mitral valve replacement. No signiﬁcant mitral leaks were found by
echocardiography post-valve implantation.
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1015Table 1 summarizes the main baseline character-
istics of the patients. All patients had a previous
history of coronary artery disease with prior coro-
nary artery bypass graft and symptomatic ischemic
cardiomyopathy (left ventricular ejection fraction
[LVEF] #30% in all patients). All had at least
1 admission for heart failure within the 6 months
prior to the procedure. Patients were rejected for
conventional mitral surgery due to left ventricular
dysfunction, previous cardiac surgery, and moder-
ate renal dysfunction. All patients had an MR $3þ
of functional origin. In 2 patients, the MR was a
consequence of a posterior leaﬂet retraction in the
context of previous inferior myocardial infarction.
In another patient, the mechanism was mainly
tenting and annular dilation.
Procedural details are provided in Table 2. The
procedure was successful and without major compli-
cations in all cases. The valve was correctly implanted
in all patients, and per-procedural TEE revealed a
minor (1þ) residual leak in 2 patients and no residual
leak in 1 patient. The transmitral gradient was
#4 mm Hg in all cases, with a mean of 3 mm Hg. The
procedural time, deﬁned as from delivery system
insertion to valve deployment, ranged from 25 to
44 min. Post-procedural complications consisted of
an acute worsening of renal function (without re-
quiring hemodialysis) in 1 patient, and per-procedural
bleeding requiring blood transfusion in another pa-
tient. There were no other in-hospital complications,
and all patients were discharged between 7 and
13 days post-intervention.Echocardiographic examinations (TTE and TEE)
before hospital discharge revealed the absence of MR
in 1 patient and trivial MR in 2 patients (Figure 3).
None of the patients presented an increase of the
aortic outﬂow gradient after valve implantation.
FOLLOW-UP OUTCOMES. There was no mortality
at 6-month follow-up. Patient 2 was hospitalized
30 days after the procedure because of gastrointes-
tinal bleeding in the context of supratherapeutic in-
ternational normalized ratio levels (international
normalized ratio: 11.7). Endoscopy revealed esopha-
geal varices and signs of recent bleeding; warfarin
and aspirin were discontinued, and clopidogrel was
started. There were no other complications.
At the 3-month follow-up, all patients showed an
improvement in NYHA functional class, DASI func-
tional status, distance walked in the 6MWT, and
quality of life (Table 3 and Central Illustration). TTE
and TEE revealed normal prosthesis function in all
patients, with a trace leak in 1 patient and no MR in
another patient. Transmitral gradients remained
similar to those observed in the immediate post-
procedural period (between 2 and 3 mm Hg). No
thrombus was observed. The mean gradients in the
left ventricular outﬂow tract (LVOT) were between 2
and 5 mm Hg, and LVEF was similar to baseline.
Functional status improvement persisted at 6 months,
with all patients in NYHA functional class #II.
CT scan images of the 3 patients at the 3-month
follow-up are shown in Figure 4. No fractures of
the valve frame were detected, nor was any erosion
of the posterior aortic wall (Figure 4). Adequate
TABLE 3 Functional Status, Echocardiography, and CT Scan Data at 3- and 6-Month Follow-Up
Patient
Baseline Functional Status 3-Month FU Functional Status 3-Month FU TEE CT Data 6-Month FU
NYHA
Functional
Class
6MWT
(m) DASI* QoL†
NYHA
Functional
Class
6MWT
(m) DASI* QoL†
LVEF
(%)
Grad
(mm Hg)
MR
Grade
LVOT
(mm Hg)
Frame
Fracture
NYHA
Functional
Class Status
1 III 386 35.0 86.2 I 419 45.5 97.1 30 3 1 4 No I Alive/no
complications
2 IV 138 7.2 61.2 II 245 19.0 83.5 25 3 1 2 No II Alive/no
readmission
3 III 336 20.7 74.0 II 405 37.5 86.5 25 2 0 5 No II Alive/no
complications
*Duke Activity Status Index score (range 0 to 58.2). †Kansas City Questionnaire score (range 0 to 100).
6MWT ¼ 6-min walk test; CT ¼ computed tomography; DASI ¼ Duke Activity Status Index; FU ¼ follow-up; Grad ¼ mean transmitral gradient; LVOT ¼ left ventricle outﬂow tract gradient;
NYHA ¼ New York Heart Association; QoL ¼ quality of life (as evaluated by Kansas City Questionnaire); TEE ¼ transesophageal echocardiography; other abbreviations as in Tables 1 and 2.
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1016space at the level of the outﬂow tract was evident
in all cases (Central Illustration).
DISCUSSION
This initial experience of TMVR with the Fortis valve
demonstrates the feasibility and safety of the pro-
cedure. Furthermore, optimal valve performance was
achieved in all cases, with no signiﬁcant residual
leaks or transvalvular gradients, and valvular func-
tion was maintained at the 3-month follow-up. No
structural failures of the device, as evaluated by
echocardiography and CT, were detected at 3
months. This translated into a signiﬁcant improve-
ment in functional status and quality of life for all
patients at the 3- and 6-month follow-ups.
There are several reports of TMVR using balloon-
expandable aortic valve systems in the mitralFIGURE 4 Cardiac Computed Tomography 3 Months After FORTIS Im
(A) Long-axis view of patient 1 showing an optimal LVOT clearance (red a
view of patient 2 at the mitral annulus level. (C) Sagittal view of patien
and the interaction between the ﬂexible FORTIS struts and the aorta at
abbreviations as in Figure 2.position in patients with severe calciﬁed mitral dis-
ease (mitral stenosis and/or mitral regurgitation) who
were deemed to be at high surgical risk (17–22).
Similar to aortic valve implantation, the presence of
severe annular mitral calciﬁcation seems to be
pivotal for ensuring valve prosthesis anchoring and
stability, and this precludes the use of these valve
platforms in the setting of nonsevere calciﬁed mitral
disease. More recently, the procedural results of the
10 ﬁrst-in-man cases using a dedicated transcatheter
mitral valve platform in patients with isolated MR
have been reported, including 5, 3, and 2 cases with
the Fortis, CardiaAQ (CardiAQ Valve Technologies,
Irvine, California), and Tiara (Neovasc, Richmond,
British Columbia, Canada) devices, respectively
(9,10,12). In addition, 2 patients had implantation of
the Tendyne valve (Tendyne Holdings Inc., Roseville,
Minnesota) (11), but the system was removed withinplantation
rrows), and no erosion in the aortic sinus side (asterisk). (B) Short-axis
t 3 showing the apical scar (black arrow) at the puncture level,
the aortic sinus level (asterisk). RCA ¼ right coronary artery; other
CENTRAL ILLUSTRATION 3- to 6-Month Follow-Up Results After TMVR
Abdul-Jawad Altisent, O. et al. J Am Coll Cardiol. 2015; 66(9):1011–9.
All patients showed an improvement in functional status (evaluated by NYHA functional class, 6MWT, and DASI) and quality of life at the 3- to 6-month
follow-up. The hemodynamic valve performance remained optimal (TEE 3D images). None of the patients presented an increase in the aortic outﬂow or
transmitral gradients. There was no alteration in the prosthesis valve stent frame structure (CT scan images). The red double-headed arrow indicates the
left ventricular outﬂow tract. 3D ¼ 3-dimensional; 6MWT ¼ 6-min walking test; Ao ¼ aorta; CT ¼ computed tomography; DASI ¼ Duke Activity Status
Index; FU ¼ follow-up; NYHA ¼ New York Heart Association; TEE ¼ transesophageal echocardiogram; TMVR ¼ transcatheter mitral valve replacement.
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10172 h after successful implantation, and the patients
ﬁnally underwent standard surgical mitral surgery.
The high periprocedural mortality rates for these ﬁrst
10 patients represent an early experience in relativelyhighly comorbid patients with no or few other ther-
apeutic options, treated mainly under compassionate
use. The main causes of mortality included technical
issues leading to valve prosthesis dislocation (n ¼ 1),
PERSPECTIVES
COMPETENCIES IN MEDICAL KNOWLEDGE:
TMVR can be performed with a low midterm com-
plication rate in patients with isolated, severe MR who
are at very high or prohibitive risk of complications
with open mitral valve surgery.
TRANSLATIONAL OUTLOOK: Additional studies
involving a larger number of patients and longer
follow-up are necessary to better deﬁne the clinical
and anatomical characteristics of the patients most
able to beneﬁt from this therapeutic approach.
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1018post-operative complications leading to multiorgan
failure (n ¼ 4), and suspected valve thrombosis
within 30 days after the procedure (n ¼ 1). Appro-
priate anatomical screening by echocardiography and
CT, as well as access point planning, seems to be key
for procedural success. In our experience, apart from
CT-based pre-planning of the optimal puncture site,
careful manual evaluation guided by TEE with the
ventricular apex exposed was very important for the
ﬁnal selection of the puncture site to achieve optimal
coaxiality of the delivery system with the native
mitral valve (Figure 2A).
Apart from technical difﬁculties, the mixed results
obtained in the overall initial TMVR experience
highlight the importance of patient selection as well
as the potential challenges of a thoracotomy and api-
cal approach. Besides the importance of noncardiac
comorbidities, the presence of an LVEF <20% may be
associated with further reduction of the LVEF after
the procedure (23,24), leading to persistent heart
failure and death. In addition, the myocardial injury
associated with the transapical approach may further
contribute to decreased LVEF (25). All patients
included in our small series had an LVEF of 25% to
30%, and none of them experienced decompensated
heart failure after the procedure. Also, potential
challenges with transapical procedures are relatively
well understood. In addition to potential myocardial
tears during transapical access hemostasis, pain
associated with left thoracotomy has been shown to
have a major negative effect on patients undergoing
transapical aortic valve procedures (26). We have
previously shown the usefulness of adequate pain
control with the use of epidural analgesia in trans-
apical aortic valve implantation (26), and this
approach was also applied to our TMVR procedures,
and may have contributed to the successful results
obtained in our initial TMVR experience.
There is no evidence concerning the most ap-
propriate antithrombotic treatment after TMVR.
After surgical mitral valve replacement with a bio-
prosthesis, all guidelines recommend selected or
systematic anticoagulation therapy in addition to
aspirin for 3 months, and then aspirin indeﬁnitely
(27). This was the regime applied in our patients
(2 were already on warfarin therapy due to atrial
ﬁbrillation and were intended to remain on warfarin
indeﬁnitely), although 1 of them presented with
gastrointestinal bleeding in the weeks after the pro-
cedure and required cessation of anticoagulation
therapy. This patient was treated with clopidogrel,
and no thromboembolic events had occurred at the
6-month follow-up. However, in May 2015, Edwards
Lifesciences temporarily halted the prospective Fortisclinical trial due to valve thrombus noted in some of
the valves. This suggests that a strict anticoagulation
regime may be needed after TMVR. Future studies are
needed to determine the best type and duration of
antithrombotic treatment after these procedures.
This is the very ﬁrst report with systematic
6-month follow-up data after TMVR. This early
follow-up showed that valve function was main-
tained, with no structural failures. The systematic
improvement in patients’ functional status and
quality of life, with no rehospitalizations due to
decompensated heart failure, are encouraging. How-
ever, a close, longer-term follow-up is needed to
conﬁrm these promising early results.
STUDY LIMITATIONS. The main limitations of this
study are the small number of patients and the lack
of long-term follow-up. After this initial experience,
a larger number of patients and a longer follow-up
will be needed to determine the ﬁnal safety and
efﬁcacy results associated with this technology.
CONCLUSIONS
In this initial experience including 3 patients, TMVR
with the Fortis mitral transcatheter heart valve was
feasible and was associated with good outcomes
at the 6-month follow-up, with a low complication
rate and sustained valve performance. Continued
advancements in anatomical evaluation, technical
ease, pre-procedural planning, and post-procedural
management will play an important role in the success
of TMVR procedures. Further studies are warranted.
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